Overview

Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer

Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the effects (good and bad) Iressa plus anastrozole has on patients with relapsed ovarian cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Brigham and Women's Hospital
Dana-Farber Cancer Institute
Treatments:
Anastrozole
Gefitinib